OBN CEO Interview: Meet the Finalists, OBN Awards 2020 - Best Established Biotech (Oncology) Company
Event Start Date: 11/05/2021 12:00
Event End Date: 11/05/2021 13:00
Sign Up To This Event
There are currently 5 spaces left.
Entries for the Best Established Biotech category were so strong this year that we created a spin-off standalone category for the top Oncology-focused finalists. Join us to hear about the exciting work that made them stand out to our judges, learn a little about each company’s story, their R&D Innovation and why they are making such an impact on the industry today.
The OBN Awards, are the most highly regarded awards event in the industry and aim to recognise and celebrate the most innovative life sciences companies across all therapy areas and functions.
Join us on Tuesday 11 May from 12:00 to 13:00 to learn more about our finalists:
Adaptimmune – Focusing on the development of novel cancer cell therapy products for people with cancer. The company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumours.
Crescendo Biologics – Developing potent multi-functional Humabody® therapeutics in oncology with a proprietary pipeline focus on CB307, a unique T-cell engager.
MiNA Therapeutics - Harnessing an innate mechanism of gene activation, their platform enables the development of new medicines that restore normal function to patients' cells.
John Harris, CEO, OBN
Adrian Rawcliffe, CEO Adaptimmune
Theodora Harold, CEO, Crescendo Biologics
Robert Habib, CEO, MiNA Therapeutics